Viridian Therapeutics, a biotech firm targeting autoimmune and rare diseases, has priced an upsized underwritten public offering of $225.0 million in 1.75% convertible senior notes due 2032. This follow-on offering aims to fund the advancement of its clinical pipeline, including its lead drug candidate for thyroid eye disease. The company did not disclose specific metrics like client numbers or revenue in this announcement.
Amount: $350.0M
Viridian Therapeutics Public Offering — Viridian Therapeutics, Inc.
